Price Alert

Aquestive Therapeutics In... (AQST)

NASDAQ: AQST · Real-Time Price · USD

4.12

0.11 (2.74%)

At close: Aug 14, 2025, 3:59 PM

4.08

-0.84%

After-hours: Aug 14, 2025, 07:56 PM EDT

2.74% (1D)

Bid	4.08
Market Cap	410.36M
Revenue (ttm)	54.23M
Net Income (ttm)	-54.24M
EPS (ttm)	-0.69
PE Ratio (ttm)	-5.96
Forward PE	-6.62
Analyst	Buy

Ask	4.25
Volume	5,945,215
Avg. Volume (20D)	1,341,054
Open	3.99
Previous Close	4.01
Day's Range	3.83 - 4.24
52-Week Range	2.12 - 5.80
Beta	1.99

About AQST

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AQST

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AQST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Aquestive Therapeutics has released their quartely earnings on Aug 11, 2025:

Revenue of $10M misses estimates by $1.22M, with -50.23% YoY decline.

EPS of -0.14 exceeds estimates by 0.04, with -366.67% YoY decline.

Next Earnings Release

Aquestive Therapeutics Inc. is scheduled to release its earnings on Nov 3, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-19.65%

Aquestive Therapeutics shares are trading lower af... Unlock content with Pro Subscription

5 months ago

+2.2%

Aquestive Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results

News

20 hours ago · zacks.com

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

2 days ago · seekingalpha.com

Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript

Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants A. Ernest Toth - Chief Financial Officer Carl N.

3 days ago · zacks.com

Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key met...

3 days ago · zacks.com

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.03 per share a year ago.

1 month ago · seekingalpha.com

Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval

Anaphylm's FDA approval process is a major catalyst, with a PDUFA date set for January 31, 2026, and potential AdCom or partnership news ahead. Anaphylm offers a needle-free, orally delivered epinephr...

1 month ago · zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

2 months ago · seekingalpha.com

Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share

Aquestive Therapeutics' Anaphylm offers a unique, non-injectable epinephrine solution for anaphylaxis, with NDA decision expected imminently. Anaphylm's advantages—wallet portability, rapid onset, and...